Rare lephants
Screener

Caribou Biosciences, Inc.

CRBU ·Healthcare, Drug Manufacturers - General, United States
Analysis › Moat Score

Moat Score — Caribou Biosciences, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 Proprietary chRDNA editing technology plus licensed foundational CRISPR-Cas9 patents from UC Berkeley/University of Vienna and a cross-license with Intellia provide meaningful IP protection.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 2 / 5 The allogeneic, off-the-shelf manufacturing model is structurally cheaper to scale than patient-specific autologous CAR-T, though this advantage is not yet proven at commercial scale.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 0 / 5 No approved products yet, so the company has no current commercial pricing power.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 0 / 5 Cell therapy development has no meaningful network effect dynamics.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 1 / 5 With no marketed product, there is no installed prescriber or patient base yet to create switching costs.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 1 / 5 Allogeneic CAR-T manufacturing could eventually support scale efficiencies, but Caribou has not yet reached commercial-scale production or approval.